All In Biotech

Drug Trial Radar · NCT02513394

PALbociclib CoLlaborative Adjuvant Study

PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer

Last checked: Nov 19, 2026Latest source record: Jun 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 5,796 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

5,796

Actual

Start

Aug 2015

Primary completion

Nov 2020

Study completion Dec 2028

Sponsor

Lead sponsor
Alliance Foundation Trials, LLC.Academic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Austrian Breast & Colorectal Cancer Study Group; NSABP Foundation Inc; PrECOG, LLC.; Breast International Group; Pfizer
First posted
Jul 31, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, two arm, international, multicenter, randomized, open-label Phase III study evaluating the addition of 2 years of palbociclib to standard adjuvant endocrine therapy for patients with HR+ / HER2- early breast cancer (EBC). The purpose of the PALLAS study is to determine whether the addition of palbociclib to adjuvant endocrine therapy will improve outcomes over endocrine therapy alone for HR+/HER2- early breast cancer. Assessment of a variety of correlative analysis, including evaluation of the effect of palbociclib in genomically defined tumor subgroups, is planned.

Conditions

  • Breast Cancer

Interventions

  • PalbociclibDrug

  • Standard Adjuvant Endocrine TherapyDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Invasive Disease Free Survival (iDFS)Time frame: 4 years

Locations

437 sites in 21 countries. Site status is shown where the registry gives one.

  • University of South Alabama Mitchell Cancer Institute

    Mobile, Alabama

  • Southern Cancer Center PC - Providence

    Mobile, Alabama

  • Katmai Oncology Group

    Anchorage, Alaska

  • Providence Alaska Cancer Center

    Anchorage, Alaska

  • Mayo Clinic in Arizona

    Phoenix, Arizona

  • Kaiser Permanente Anaheim Medical Center

    Anaheim, California

  • Kaiser Permanente Baldwin Park Medical Center

    Baldwin Park, California

  • Kaiser Permanente Bellflower Medical Center

    Bellflower, California

  • Kaiser Permanente Fontana Medical Center

    Fontana, California

  • Marin Cancer Care

    Greenbrae, California

  • Marin Cancer Center

    Greenbrae, California

  • Kaiser Permanente Harbor City Medical Center

    Harbor City, California

  • Kaiser Permanente Irvine Medical Center

    Irvine, California

  • UCSD Moores Cancer Center

    La Jolla, California

  • Long Beach Memorial Medical Center - Todd Cancer Institute

    Long Beach, California

  • Kaiser Permanente Sunset Medical Center

    Los Angeles, California

  • Cedars Sinai Medical Center

    Los Angeles, California

  • Kaiser Permanente Oakland Medical Center

    Oakland, California

  • Palo Alto Medical Foundation Health Care

    Palo Alto, California

  • Kaiser Permanente Panorama City Medical Center

    Panorama City, California

  • Kaiser Permanente Riverside Medical Center

    Riverside, California

  • Kaiser Permanente Roseville Medical Center

    Roseville, California

  • Kaiser Permanente Sacramento Medical Center

    Sacramento, California

  • University of California

    San Diego, California

  • Kaiser Permanente San Diego Medical Center

    San Diego, California

  • Sharp Memorial Hospital

    San Diego, California

  • Kaiser Permanente San Francisco Medical Center

    San Francisco, California

  • UCSF Helen Diller Comprehensive Cancer Center

    San Francisco, California

  • Kaiser Permanente San Jose Medical Center

    San Jose, California

  • Kaiser Permanente San Leandro Medical Center

    San Leandro, California

  • Kaiser Permanente San Marcos Medical Center

    San Marcos, California

  • Kaiser Permanente Santa Clara Medical Center

    Santa Clara, California

  • Kaiser Permanente South San Francisco Medical Center

    South San Francisco, California

  • Stanford Women's Cancer Center

    Stanford, California

  • Kaiser Permanente Vallejo Medical Center

    Vallejo, California

  • Kaiser Permanente Walnut Creek Medical Center

    Walnut Creek, California

  • Kaiser Permanente Cadillac Medical Center

    West Los Angeles, California

  • Kaiser Permanente Woodland Hills Medical Center

    Woodland Hills, California

  • Western States Cancer Research NCORP

    Denver, Colorado

  • Hartford Hospital

    Hartford, Connecticut

Showing 40 of 437 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.